Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Phibro Animal HealthPAHC -3.41%75 PS Ratio is 0.93 as of Aug. 08, 2026, which is 15% below its 10-year median of 1.10. GuruFocus rates PAHC with a GF Score™ of 75/100 and a GF Value™ of $29.54 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 953 Drug Manufacturers companies, Phibro Animal Health ranks better than 75.76% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Phibro Animal Health's share price is $34.26.
Phibro Animal Health's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $36.68. Hence, Phibro Animal Health's PS Ratio for today is 0.93.
The historical rank and industry rank for Phibro Animal Health's PS Ratio or its related term are showing as below:
PAHC'
s PS Ratio Range Over the Past 10 Years
Min: 0.4 Med: 1.1 Max: 2.5
Current: 0.98
During the past 13 years, Phibro Animal Health's highest PS Ratio was 2.50. The lowest was 0.40. And the median was 1.10.
PAHC's PS Ratio is ranked better than 75.76% of 953
companies
in the Drug Manufacturers industry
Industry Median: 2.33
vs PAHC: 0.98
During the past 12 months, the average Revenue per Share Growth Rate of Phibro Animal Health was 25.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 11.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 9.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 4.40% per year.
During the past 13 years, Phibro Animal Health's highest 3-Year average Revenue per Share Growth Rate was 11.10% per year. The lowest was -4.30% per year. And the median was 2.25% per year.
Phibro Animal Health (NAS:PAHC) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Phibro Animal Health PS Ratio Related Terms
Phibro Animal Health PS Ratio Historical Data
* Premium members only.
The historical data trend for Phibro Animal Health's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Phibro Animal Health's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phibro Animal Health PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Phibro Animal Health's PS Ratio distribution charts can be found below:
* The bar in red indicates where Phibro Animal Health's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Phibro Animal Health's Share Price of today is $34.26. Phibro Animal Health's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $36.68.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Phibro Animal Health (PAHC) has a PS Ratio of 0.93 as of Aug. 08, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Phibro Animal Health and its competitors. This is 15% below median its historical median of 1.10. Over the past decade, Phibro Animal Health's PS Ratio has ranged from 0.40 to 2.50. According to the industry distribution chart, Phibro Animal Health ranks #231 out of 953 companies in the Drug Manufacturers industry, placing it in the top 24.2%.
Is Phibro Animal Health's PS Ratio too high?
Phibro Animal Health's current PS Ratio of 0.93 is 15% below median its 10-year median of 1.10. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 2.50. The Drug Manufacturers industry median PS Ratio is 2.33. Phibro Animal Health's value of 0.93 is 60.1% below this industry median. Based on the distribution chart, Phibro Animal Health ranks #231 out of 953 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Phibro Animal Health has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Phibro Animal Health's PS Ratio compare to PRGO and HROW?
According to the Drug Manufacturers industry distribution chart, Phibro Animal Health ranks #231 out of 953 companies for PS Ratio. This places Phibro Animal Health in the top 24% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.33. Phibro Animal Health's value of 0.93 is 60.1% below this benchmark. Historically, Phibro Animal Health's own PS Ratio has ranged from 0.40 to 2.50 over the past decade. While the company's 10-year median is 1.10 vs. the industry median of 2.33, Phibro Animal Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.33, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Phibro Animal Health's current PS Ratio of 0.93 is 60.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Phibro Animal Health and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phibro Animal Health's current PS Ratio is 0.93, which is 15% below median its own 10-year median of 1.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phibro Animal Health stock overvalued right now?
Based on GuruFocus' analysis, Phibro Animal Health (PAHC) is currently considered Modestly Overvalued. The stock's GF Value™ is $29.54, compared to a current price of $34.26 — trading 16% above its estimated fair value. The current PS Ratio is 0.93, which is 15% below median its 10-year median of 1.10 and 60.1% below the Drug Manufacturers industry median of 2.33. Phibro Animal Health's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Phibro Animal Health (PAHC), the current PS Ratio is 0.93 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Phibro Animal Health (PAHC) Overvalued in 2026?
Based on GuruFocus' analysis, Phibro Animal Health stock appears to be overvalued.
The current stock price of $34.26 is trading 16% above its estimated GF Value™ of $29.54.
GuruFocus considers Phibro Animal Health to be Modestly Overvalued.
Key valuation signals for PAHC:
PS Ratio: 0.93 (15% below median its 10-year median of 1.10)
GF Value™: $29.54 vs. price of $34.26 (16% above fair value)
Industry Position: 60.1% below the Drug Manufacturers median (#231 of 953)
No single metric tells the full story. See the PAHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
75GF Score
Get the complete analysis for PAHC
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PAHC has been successfully added to your 
